MEDICA – Düsseldorf / Germany/14-17 Nov. 2022
    World Forum for Medicine/ HALL 3/D 29-1
    New IVD antibody for Breast Pathology
    TRPS1 rabbit monoclonal antibody
    New Products
    July, 2022
    MMR related antibodies
    DNA mismatch repair (MMR) system
    Rabbit Monoclonal antibodies
    RAbMono™: Superior specificity, low background, high affinity
    Unique and Specificity
    MonoMAb™ antibodies
    We are hiring
    Operation Manager/Supervisor
    Zeta develops highly specific and sensitive primary antibodies suitable for routine and differential diagnosis in anatomic pathology laboratories.
    MonoMAb™ antibodies are uniquely developed Monospecific antibodies by running the selective clones through a high throughput protein chip to demonstrate and select the most specific one.
    RAbMono™ Rabbit monoclonal antibodies are uniquely produced and target-validated for IHC on FFPE tissue sections. They stand out because of their superior specificity, low background, and high affinity.

    About
    Corporation

    Zeta Corporation is a biomedical company based in Southern California with ISO 13485 and FDA certifications. Zeta develops, manufactures, and distributes highly specific and sensitive IVD antibodies for Pathology/IHC on FFPE tissue sections.

    Specifically, Zeta designs and develops tumor-specific biomarkers using cutting-edge technologies to uniquely select the immunogens for our famed  MonoSpecific monoclonal antibodies. Zeta is committed to providing the highest quality of antibodies to aid pathologists in diagnosing human diseases.